CN112930183A - 大麻二酚联合组合物 - Google Patents

大麻二酚联合组合物 Download PDF

Info

Publication number
CN112930183A
CN112930183A CN201980057334.3A CN201980057334A CN112930183A CN 112930183 A CN112930183 A CN 112930183A CN 201980057334 A CN201980057334 A CN 201980057334A CN 112930183 A CN112930183 A CN 112930183A
Authority
CN
China
Prior art keywords
glucosamine
cbd
composition
disease
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980057334.3A
Other languages
English (en)
Chinese (zh)
Inventor
G·瓦克宁
T·巴尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Partner Science Co ltd
Original Assignee
Partner Science Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Partner Science Co ltd filed Critical Partner Science Co ltd
Publication of CN112930183A publication Critical patent/CN112930183A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201980057334.3A 2018-07-02 2019-07-01 大麻二酚联合组合物 Pending CN112930183A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692865P 2018-07-02 2018-07-02
US62/692,865 2018-07-02
PCT/US2019/040043 WO2020009950A1 (en) 2018-07-02 2019-07-01 Cannabidiol combination compositions

Publications (1)

Publication Number Publication Date
CN112930183A true CN112930183A (zh) 2021-06-08

Family

ID=69060564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980057334.3A Pending CN112930183A (zh) 2018-07-02 2019-07-01 大麻二酚联合组合物

Country Status (8)

Country Link
US (1) US20210275556A1 (https=)
EP (1) EP3817750A4 (https=)
JP (1) JP2021532171A (https=)
CN (1) CN112930183A (https=)
AU (1) AU2019299213A1 (https=)
BR (1) BR112020027097A2 (https=)
CA (1) CA3105082A1 (https=)
WO (1) WO2020009950A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017023A2 (pt) 2018-02-23 2021-03-02 Nicola Michael Spirtos terapêutica à base de cannabis e método de uso
IT201900016709A1 (it) * 2019-09-19 2021-03-19 Aqma Italia S P A Composizione antidolorifica e antinfiammatoria ad uso locale
US20210212950A1 (en) * 2020-01-15 2021-07-15 Resurgent Pharmaceuticals, Inc. Orally deliverable formulation to prevent all cause mortality and cardiovascular events
US11364255B2 (en) * 2020-07-01 2022-06-21 Karallief, Inc. Therapeutic herbal compositions for improving joint health
BR102020023664A2 (pt) * 2020-07-02 2022-01-11 Yuzu Llc Composições compreendendo canabidiol e flavononas
EP4182026A4 (en) * 2020-07-17 2024-10-02 India Globalization Capital, Inc. COMPOSITION BASED ON CANNABIDIOL (CBD) AND METHOD FOR TREATING PAIN

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444081A1 (en) * 2010-10-19 2012-04-25 Parenteral, A.S. A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
US20160038531A1 (en) * 2014-08-05 2016-02-11 James Sullivan Fast acting joint relief formulations
US20160228385A1 (en) * 2015-02-05 2016-08-11 Colorado Can Llc Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
US20170266127A1 (en) * 2016-03-18 2017-09-21 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
CN110575432A (zh) * 2018-06-08 2019-12-17 汉义生物科技（北京）有限公司 一种含有大麻二酚的组合物及其在动物用品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887497B2 (en) * 2002-12-19 2005-05-03 Vitacost.Com, Inc. Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
AU2006249771A1 (en) * 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
JP5204578B2 (ja) * 2007-07-31 2013-06-05 全薬工業株式会社 関節痛改善用組成物、関節痛改善剤、あるいは食品
SG10201402819WA (en) * 2014-06-02 2016-01-28 Beauty Nation Pte Ltd Composition for prevention and treatment of joint pain and the method of preparation thereof
US10398776B1 (en) * 2014-11-03 2019-09-03 Essential Green Goodness LLC Phonophoretic cannabidiol composition and transdermal delivery system
US10945967B2 (en) * 2017-05-30 2021-03-16 Jae Wang. Song Formulations of a transdermal patch for pain management
US20190000794A1 (en) * 2017-12-27 2019-01-03 Daniel S. Tanaka Transmucosal cannabinoid formulation including a chitosan excipeint
CN112969452A (zh) * 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
WO2020021545A1 (en) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol and glucosamine for treating inflammatory joint diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444081A1 (en) * 2010-10-19 2012-04-25 Parenteral, A.S. A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
US20160038531A1 (en) * 2014-08-05 2016-02-11 James Sullivan Fast acting joint relief formulations
US20160228385A1 (en) * 2015-02-05 2016-08-11 Colorado Can Llc Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
US20170266127A1 (en) * 2016-03-18 2017-09-21 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
CN110575432A (zh) * 2018-06-08 2019-12-17 汉义生物科技（北京）有限公司 一种含有大麻二酚的组合物及其在动物用品中的应用

Also Published As

Publication number Publication date
EP3817750A4 (en) 2022-05-04
WO2020009950A1 (en) 2020-01-09
AU2019299213A1 (en) 2021-02-11
BR112020027097A2 (pt) 2021-03-30
CA3105082A1 (en) 2020-01-09
JP2021532171A (ja) 2021-11-25
US20210275556A1 (en) 2021-09-09
EP3817750A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
CN112930183A (zh) 大麻二酚联合组合物
EP1765314B1 (en) Pharmaceutical compositions for the treatment of disease and symptoms in rheumatoid arthritis
CA2656698A1 (en) Cannabinoids for use in the treatment of neuropathic pain
JP7322094B2 (ja) 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤
EP4251181A1 (en) Compositions and methods for treating neurological conditions
JP5409602B2 (ja) 慢性疼痛の治療におけるジミラセタムの使用
US11523998B2 (en) Anti-inflammatory formulations and uses thereof including a combination of palmitoylethanolamide and plant-based polyphenols
JP2002518438A (ja) 不安状態または鬱病による神経および行動変化の予防および／または治療のための神経保護組成物
KR102350519B1 (ko) 말초성 염증 및 통증을 감소시키는데 유용한 울금 및 에키네시아 안구스티폴리아의 추출물을 함유하는 조성물
AU2006232644B2 (en) Anti-inflammatory formulation
JP2004516257A (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
JP2022543703A (ja) Ｃｂｄ製剤およびその使用
EA038052B1 (ru) Комбинация, содержащая пальмитоилэтаноламид, для лечения хронической боли
GB2510659A (en) Synergistic combination of alkylamine compounds and herbal sedatives for the treatment of insomnia, anxiety and depression
CN100522983C (zh) 梓醇及其同系物的医药用途
JPWO2017111069A1 (ja) 止痒剤
US20090156551A1 (en) Novel composition
WO2007054348A1 (de) Neue arzneimittel
US20090142419A1 (en) Anti-inflammatory extract and agent and method for the production thereof
RU2240131C1 (ru) Средство "артровит" для профилактики и лечения артритов и артрозов
EP1227826B1 (en) Composition comprising an extract of perna canaliculus, methylsulfonylmethane and glucosamine and use thereof
WO2009063499A2 (en) A herbomineral formulation for treating sickle cell disease
WO2016107894A1 (en) Composition for joint and cartilage disorders comprising flurbiprofen, glucosamine sulfate, chondroitin sulfate, hyaluronic acid and methylsulfonylmethane
CA2958169A1 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
KR20230143155A (ko) 관절염과 건선을 위한 보충제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210608